08/06/2024
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/31/2024
4:15 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2024
3:23 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
4:15 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/11/2024
11:59 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/02/2024
4:30 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
|
07/02/2024
3:30 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2024
2:13 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/18/2024
4:31 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2024
3:39 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/14/2024
3:34 PM | Olema Pharmaceuticals (Subject)
Point72 Asset Management, L.P. (Filed by)
| Form SC 13G | |
06/06/2024
5:49 PM | Logos Global Management LP (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13D/A | |
06/06/2024
9:02 AM | Logos Opportunities Fund I LP (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/06/2024
9:05 AM | Logos Opportunities Fund II LP (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/04/2024
8:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/04/2024
2:09 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/03/2024
1:55 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/31/2024
11:17 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
6:06 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/08/2024
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/07/2024
4:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/06/2024
3:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/30/2024
2:25 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024
4:10 PM | Olema Pharmaceuticals (Filer)
| Form DEFA14A | |
04/26/2024
4:15 PM | Olema Pharmaceuticals (Filer)
| Form ARS | |
03/29/2024
4:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/28/2024
10:02 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/22/2024
3:31 PM | Deep Track Capital, LP (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G | |
03/20/2024
4:30 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/11/2024
3:31 PM | Olema Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/11/2024
3:15 PM | Olema Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/06/2024
4:36 PM | Olema Pharmaceuticals (Issuer)
RAPPAPORT ANDREW (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
4:30 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
1:26 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/14/2024
11:53 AM | Kynam Capital Management, LP (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/12/2024
4:16 PM | Olema Pharmaceuticals (Filer)
| Form 424B3 | |
02/12/2024
11:21 AM | JANUS HENDERSON GROUP PLC (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/11/2024
11:15 PM | Olema Pharmaceuticals (Filer)
| Form EFFECT | |
02/05/2024
4:30 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
4:30 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
EXPOSED: Hotspot Dates for popular stocks (Ad) Did you know almost every stock in the market has multiple “Hotspot Dates”?
They indicate when the stock has gone up on the same dates… at the same time… FOR DECADES
For example, have you ever traded a stock called Constellation Energy (ticker: CEG)?
Maybe not…
Energy stocks haven’t received much love over the past 12 months.
But anybody who knew about the “Hotspot Date” during the last week in January… Go here to get Roger’s top FIVE Hotspot Stocks for This Month! |
02/05/2024
4:30 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
4:30 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
4:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/01/2024
2:24 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2024
1:58 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/29/2024
4:25 PM | BlackRock Inc. (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13G | |
01/29/2024
6:30 AM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
6:30 AM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/08/2024
8:07 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/08/2024
7:18 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/05/2024
4:25 PM | Olema Pharmaceuticals (Filer)
| Form 424B5 | |
01/05/2024
4:26 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2024
4:30 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/18/2023
5:30 PM | Graham G. Walmsley (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2023
4:55 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/12/2023
4:55 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/08/2023
3:19 PM | Asefaw Senai (Reporting)
Olema Pharmaceuticals (Issuer)
Paradigm BioCapital Advisors GP LLC (Reporting)
Paradigm Biocapital Advisors LP (Reporting)
Paradigm BioCapital International Fund Ltd. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/07/2023
7:30 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 3/A | |
12/07/2023
7:30 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
6:48 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/05/2023
4:15 PM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/01/2023
4:15 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/30/2023
9:20 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
6:00 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
6:00 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
6:00 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
6:00 PM | Olema Pharmaceuticals (Issuer)
Zojwalla Naseem (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
6:00 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
2:25 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
2:04 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
2:12 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
1:35 PM | Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/22/2023
1:42 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023
2:11 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023
2:16 PM | Bohen Sean (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023
1:49 PM | Kovacs Shane William Charles (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/21/2023
1:52 PM | Olema Pharmaceuticals (Subject)
Zojwalla Naseem (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2023
4:30 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/03/2023
8:39 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/03/2023
3:53 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/02/2023
7:50 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/02/2023
3:46 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/02/2023
3:21 PM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/01/2023
3:49 PM | Myles David C. (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/31/2023
9:38 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2023
6:45 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/18/2023
3:46 PM | Olema Pharmaceuticals (Filer)
| Form 8-K/A | |
10/17/2023
3:42 PM | Garland J. Scott (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/17/2023
3:43 PM | Garland J. Scott (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/17/2023
6:33 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
This P/L chart will make your eyes pop (Ad) Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months.
You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists…
It’s a revolutionary software system that tracks the moves of institutional investors…. in real time… Go here to watch the most recent trading workshop video at no charge. |
10/10/2023
6:17 AM | Olema Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/29/2023
10:05 AM | Harmon Cyrus (Reporting)
Olema Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/21/2023
4:12 PM | Asefaw Senai (Reporting)
Olema Pharmaceuticals (Issuer)
Paradigm BioCapital Advisors GP LLC (Reporting)
Paradigm Biocapital Advisors LP (Reporting)
Paradigm BioCapital International Fund Ltd. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/14/2023
3:23 PM | BIOTECHNOLOGY VALUE FUND L P (Filed by)
Olema Pharmaceuticals (Subject)
| Form SC 13D/A | |
09/14/2023
3:25 PM | BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
Olema Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/14/2023
3:14 PM | Olema Pharmaceuticals (Filer)
| Form D
Notice of Exempt Offering of Securities | |
09/13/2023
4:22 PM | Olema Pharmaceuticals (Subject)
Paradigm Biocapital Advisors LP (Filed by)
| Form SC 13G/A | |
